File Entry: Krishnasarma Pathy*Flu Viruses Open Acc J of Toxicol Copyright © All rights are reserved by Krishnasarma Pathy

Krishnasarma Pathy*
Head of QC/QA, IPL Research Centre, India
Submission: October 24, 2017; Published: March 07, 2018
*Corresponding author: Krishnasarma Pathy, Head of QC/QA, IPL Research Centre, India, Tel: 9919188895

Human H1N1 pandemic developed from the originally localized Mexican source early in the spring 2009. For the emergency created by the epidemic of influence of the pigs in Mexico it was correct not to create alarmism being victims of bad information. Cytokine storm should be mentioned as one of the key pathogenic events contributing to the overall mortality in substantial portion of patients. If active immunization is assumed to be preventive measure of proven efficacy, clinicians are still in doubt how to treat a complicated course of infection. The possibility that the virus arrives in other parts of the world is real as for all the types of influence virus. In order that a strain has a wide distribution, its antigenic characteristics must ensure that it escapes the neutralization of antibodies of the host and of the surrounding population. So the outbreaks will happen with those strains that have dominant antigens that fit the deficiency, or better, the absences of antibody in the population.
It seems, in conclusion that the flu virus shows ability and an aptitude for survival built on the possibility of emergence of new models that allow the virus being confused easily through populations still partly immune to previous antigenic forms. According to this view, the changes in the influenza A can be designed in single meaning, in the context of a principle and of an evolutionary progress, from Burnet said immunological drift or steering immunology. The antiviral drugs (inhibitors of the neuraminidases, receptor of the virus surface) should be assumed within 48 hours by the appearance of the influence symptoms and for the subjects that have had a close contact with people infected by the flu virus. The vaccination against the influence is the most effective method to prevent the illness.
1. Neuraminidases inhibitors intake, which prevent adhering of viral capsid to the eukaryotic (e.g. mammal or human) cell membrane and “decoating” of RNA into cytosol. Different pharmaceutical markets, with different rate of success, had experiences with oseltamivir, zanamivir and peramivir, applied through several dosing regimens and routes of administration and consequently choice of drug forms used,
2. Bacterial super infections antibiotics treatment, most commonly situated in lower respiratory tract, according to available evidence-based guidelines on hospital acquired pneumonia management,
3. Low dose cortisol analogues are proper only with developed respiratory distress syndrome and together with neuraminidases inhibitor. High doses are not recommended even as adjuvant therapy and have neither proven efficacy nor safety in this indication.
4. From the moment that we find the isolation of a new flu virus, we must wait for the preparation of a new specific vaccine that will be ready for the next influence season in autumn.